April 1, 2019

Verseon Corporation (“Verseon” or the “Company”)

New TIDM and ISIN for Subscription Shares

FREMONT, Calif.—Verseon, a clinical-stage pharmaceutical company developing disruptive life-science technologies to advance global health, today announces that the Subscription Shares announced on March 19, 2019 will trade under a separate and new TIDM, ‘VER2’. The Subscription Shares will also have a new ISIN, USU9221J1171, and SEDOL Code, BJ21MV8. Due to US securities laws, the Subscription Shares that will trade under VER2 are Regulation S restricted for a period of twelve months.

Verseon’s existing common shares will remain unchanged and continue to trade under the existing ticker, ‘VERS’, and existing ISIN and SEDOL.

About Verseon

Verseon Corporation (AIM:VERS) is developing disruptive life-science technology to advance global health. The clinical-stage company is using its proprietary, computational drug discovery platform to discover new drug candidates that are unlikely to be found using conventional methods. Pairing its computational engines with a comprehensive in-house chemistry and biology workflow, the company has built a growing pipeline of drug programs. Verseon currently has four active drug programs in the areas of anticoagulation, diabetic macular edema, hereditary angioedema, and oncology.

Find us on Twitter and LinkedIn.

-Ends-

For further information please contact:

Verseon Corporation www.verseon.com
Sebastian Wykeham / Tina Schlafly +1 (510) 225 9000
   
Arden Partners (NOMAD and Joint Broker)  
Ruari McGirr / Ciaran Walsh / Alex Penney +44 (0) 20 7614 5900
   
Cantor Fitzgerald Europe (Joint Broker)  
Phil Davies +44 (0) 20 7894 7000
   

For financial and business media enquiries, please contact

Buchanan Communications Ltd (PR Advisors)
Henry Harrison-Topham / Jamie Hooper +44 (0) 20 7466 5000
   

For trade and pharma media enquiries, please contact

Vane Percy & Roberts
Simon Vane Percy +44 (0) 1737 821 890

Our pledge

Verseon is committed to growth through innovation, building value for its shareholders while respecting its responsibilities as a good corporate citizen